1. Chung, G.T., Cha, J.O., Han, S.Y., Jang, H.S., Lee, K.M., Yoo, J.I., Yoo, J.S., Kim, H.B., Eun, S.H., Kim, B.S., et al. 2010. Nationwide surveillance study of vancomycin intermediate Staphylococcus aureus strains in Korean hospitals from 2001 to 2006. J. Microbiol. Biotechnol. 20, 637–642.
2. Clinical and Laboratory Standards Institute (CLSI). 2007. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; Approved standard, 7th ed. Clinical and Laboratory Standards Institute Document M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA, USA.
3. Cui, L., Lian, J.Q., Neoh, H.M., Reyes, E., and Hiramatsu, K. 2005. DNA microarray-based identification of genes associated with glycopeptide resistance in Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 3404–3413.
4. Cui, L., Neoh, H.M., Shoji, M., and Hiramatsu, K. 2009. Contribution of vraSR and graSR point mutation to vancomycin resistance in vancomycin intermediate Staphylococcus aureus. Antimicrob. Agents Chemother. 53, 1231–1234.
5. Deresinski, S. 2005. Methicillin-resistant Staphylococcus aureus: An evolutionary, epidemiologic, and therapeutic odyssey. Clin. Infect. Dis. 40, 562–573.